How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

8,670 results for

Atopic Dermatitis

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Pimecrolimus for the Treatment of Adults with Atopic Dermatitis, Seborrheic Dermatitis, or Psoriasis: A Review of Clinical and Cost-Effectiveness

Pimecrolimus for the Treatment of Adults with Atopic Dermatitis, Seborrheic Dermatitis, or Psoriasis: A Review of Clinical and Cost-Effectiveness Pimecrolimus for the Treatment of Adults with Atopic Dermatitis, Seborrheic Dermatitis, or Psoriasis: A Review of Clinical and Cost-Effectiveness | CADTH.ca Find the information you need Pimecrolimus for the Treatment of Adults with Atopic Dermatitis, Seborrheic Dermatitis, or Psoriasis: A Review of Clinical and Cost-Effectiveness Pimecrolimus (...) for the Treatment of Adults with Atopic Dermatitis, Seborrheic Dermatitis, or Psoriasis: A Review of Clinical and Cost-Effectiveness Published on: September 25, 2017 Project Number: RC0919-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of pimecrolimus for the treatment of adults with atopic dermatitis? What is the clinical effectiveness of pimecrolimus for the treatment of adults with seborrheic dermatitis? What

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

2. Dupilumab (atopic dermatitis) - Benefit assessment according to §35a Social Code Book (SGB) V

Dupilumab (atopic dermatitis) - Benefit assessment according to §35a Social Code Book (SGB) V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Dupilumab (atopische Dermatitis) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 27 February 2018). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A17-63 (...) Dupilumab (atopic dermatitis) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A17-63 Version 1.0 Dupilumab (atopic dermatitis) 27 February 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Dupilumab (atopic dermatitis) - Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded on: 1 December

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

3. Atopic dermatitis

Atopic dermatitis Evidence Maps - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4

2018 Trip Evidence Maps

4. Dupilumab (Dupixent) in adults with atopic dermatitis

Dupilumab (Dupixent) in adults with atopic dermatitis Prescrire IN ENGLISH - Spotlight ''Dupilumab (Dupixent°) in adults with atopic dermatitis'', 1 May 2019 {1} {1} {1} | | > > > Dupilumab (Dupixent°) in adults with atopic dermatitis Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight In the May issue of Prescrire International: Dupilumab (Dupixent (...) °) in adults with atopic dermatitis FREE DOWNLOAD Dupilumab (Dupixent°), a monoclonal antibody, is an option for very troublesome eczema after failure of ciclosporin. Full text available for free download. Summary Atopic dermatitis (also called atopic eczema) is a chronic relapsing-remitting inflammatory skin condition. The severity of cutaneous symptoms and their impact on daily life vary greatly from one patient to another. Dupilumab (Dupixent°, Sanofi Aventis) is a monoclonal antibody directed against

2019 Prescrire

6. Development and content validity of new patient-reported outcome questionnaires to assess the signs and symptoms and impact of atopic dermatitis: The Atopic Dermatitis Symptom Scale (ADerm-SS) and the Atopic Dermatitis Impact Scale (ADerm-IS). (PubMed)

Development and content validity of new patient-reported outcome questionnaires to assess the signs and symptoms and impact of atopic dermatitis: The Atopic Dermatitis Symptom Scale (ADerm-SS) and the Atopic Dermatitis Impact Scale (ADerm-IS). Atopic dermatitis (AD) is a chronic, relapsing skin condition, with signs and symptoms that impact patients' lives and are best measured from the patient perspective. Therefore, there is a need for AD-specific questionnaires that are consistent with Food (...) harmonized and used to construct two draft PRO questionnaires: the Atopic Dermatitis Symptom Scale (ADerm-SS; 11 items) and the Atopic Dermatitis Impact Scale (ADerm-IS; 10 items). The content validity and questionnaire content were evaluated via qualitative concept elicitation/cognitive debriefing interviews with adult patients with moderate to severe AD.From the literature (N = 13 articles), 13 sign and symptom and 43 impact concepts were identified, while 21 sign and symptom and 48 impacts were

Full Text available with Trip Pro

2018 Current medical research and opinion

7. Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2. (PubMed)

Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2. Background: Atopic dermatitis (AD) profoundly affects quality of life (QoL). Dupilumab significantly improves clinical outcomes, is well tolerated, and approved to treat inadequately controlled moderate-to-severe AD in adults; however, its effect

Full Text available with Trip Pro

2019 Journal of Dermatological Treatment

8. Dupilumab and Crisaborole for Atopic Dermatitis: Effectiveness and Value

Dupilumab and Crisaborole for Atopic Dermatitis: Effectiveness and Value ©Institute for Clinical and Economic Review, 2017 Dupilumab and Crisaborole for Atopic Dermatitis: Effectiveness and Value Final Evidence Report and Meeting Summary June 8, 2017 Prepared for ©Institute for Clinical and Economic Review, 2017 Page i Final Evidence Report – Atopic Dermatitis ICER Staff University of Washington School of Pharmacy Modeling Group David M. Rind, MD, MSc Chief Medical Officer, Institute (...) -effectiveness model, and the resulting ICER reports do not necessarily represent the views of the UW. DATE OF PUBLICATION: June 8, 2017 We would also like to thank Patricia Synnott, Matt Seidner, and Noah Mwandha for their contributions to this report. ©Institute for Clinical and Economic Review, 2017 Page ii Final Evidence Report – Atopic Dermatitis Return to Table of Contents About ICER The Institute for Clinical and Economic Review (ICER) is an independent non-profit research organization that evaluates

2017 California Technology Assessment Forum

9. Atopic Dermatitis in America Study: a cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population. (PubMed)

Atopic Dermatitis in America Study: a cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population. Population-based estimates on the prevalence of atopic dermatitis in adults vary widely. The objectives of this study were to determine the prevalence of atopic dermatitis in the population of the United States, the distribution of disease severity, and its impact on health-related quality of life. Among 1,278 participating adults (...) , the prevalence (95% confidence interval) of atopic dermatitis was 7.3% (5.9-8.8). Overall, 60.1% (56.1-64.1) of participants were classified as having mild, 28.9% (25.3-32.7) as having moderate, and 11% as having severe (8.6-13.7) disease. Patients with atopic dermatitis and those with more severe disease had higher scores in the dermatology life quality index (mean [standard deviation] for AD patients = 4.71 [6.44] vs. control individuals = 0.97 [2.12]) (P < 0.001) and the hospital anxiety (mean [standard

Full Text available with Trip Pro

2018 Journal of Investigative Dermatology

10. Report from the National Institute of Allergy and Infectious Diseases Workshop on "Atopic Dermatitis and the Atopic March: Mechanisms and Interventions". (PubMed)

Report from the National Institute of Allergy and Infectious Diseases Workshop on "Atopic Dermatitis and the Atopic March: Mechanisms and Interventions". Atopic dermatitis (AD) affects up to 20% of children worldwide and is an increasing public health problem, particularly in developed countries. Although AD in infants and young children can resolve, there is a well-recognized increased risk of sequential progression from AD to other atopic diseases, including food allergy (FA), allergic (...) rhinitis, allergic asthma, and allergic rhinoconjunctivitis, a process referred to as the atopic march. The mechanisms underlying the development of AD and subsequent progression to other atopic comorbidities, particularly FA, are incompletely understood and the subject of intense investigation. Other major research objectives are the development of effective strategies to prevent AD and FA, as well as therapeutic interventions to inhibit the atopic march. In 2017, the Division of Allergy, Immunology

2019 Journal of Allergy and Clinical Immunology

11. Effect of dupilumab on atopic manifestations in patients treated for atopic dermatitis in real life practice. (PubMed)

Effect of dupilumab on atopic manifestations in patients treated for atopic dermatitis in real life practice. Dupilumab has demonstrated efficacy in atopic dermatitis (AD)1-3 , asthma4 , perennial allergic rhinitis5 and chronic sinusitis6 . The objectives of this prospective observational, single-centre study were to assess 1) dupilumab efficacy in real-life practice and 2) the evolution of atopic co-morbidities and specific immunoglobulin E (IgE) levels during dupilumab treatment. This article

2019 British Journal of Dermatology

12. Immune dysregulation and Th2 polarization are associated with atopic dermatitis in heart-transplant children: A delicate balance between risk of rejection or atopic symptoms. (PubMed)

Immune dysregulation and Th2 polarization are associated with atopic dermatitis in heart-transplant children: A delicate balance between risk of rejection or atopic symptoms. Atopic dermatitis (AD) has a high incidence in heart-transplant children, and the reason why there is more AD after transplantation is still unknown. We conducted a cross-sectional study comparing 11 AD and 11 non-AD age-matched heart-transplant children, to assess which immune alterations are related to AD (...) understanding of atopic disorders in transplanted children.© 2019 The American Society of Transplantation and the American Society of Transplant Surgeons.

2019 American Journal of Transplantation

13. Crisaborole for adults, adolescents and children with atopic dermatitis

Crisaborole for adults, adolescents and children with atopic dermatitis Crisaborole for adults, adolescents and children with atopic dermatitis Crisaborole for adults, adolescents and children with atopic dermatitis NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Crisaborole for adults, adolescents and children with atopic dermatitis (...) . Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2016 Authors' objectives Atopic dermatitis, also known as eczema, is a long term condition that affects the skin. People with atopic dermatitis have sore, dry skin that causes intense itching, which can ooze and weep. This can lead to skin infections and trouble sleeping. It usually starts in infancy and can sometimes last into adulthood. Crisaborole is a new anti-inflammatory cream for atopic dermatitis. Some

2016 Health Technology Assessment (HTA) Database.

14. Methotrexate in atopic eczema. Comments to: Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. (PubMed)

Methotrexate in atopic eczema. Comments to: Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. 30520142 2019 01 10 1468-3083 2018 Dec 05 Journal of the European Academy of Dermatology and Venereology : JEADV J Eur Acad Dermatol Venereol Methotrexate in atopic eczema. Comments to: Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. 10.1111/jdv.15386 Goujon C C

2018 Journal of the European Academy of Dermatology and Venereology

15. Study protocol to investigate the environmental and genetic aetiology of atopic dermatitis: the Indonesian Prospective Study of Atopic Dermatitis in Infants (ISADI). (PubMed)

Study protocol to investigate the environmental and genetic aetiology of atopic dermatitis: the Indonesian Prospective Study of Atopic Dermatitis in Infants (ISADI). Atopic dermatitis (AD) is the most common skin disorder in young children worldwide, with a high impact on morbidity and quality of life. To date, no prospective study has been published on the incidence and potential predictors of AD in South East Asian populations. The Indonesian Prospective Study of Atopic Dermatitis in Infants

Full Text available with Trip Pro

2017 BMJ open

16. Prenatal perfluorooctanoic acid exposure and glutathione s-transferase T1/M1 genotypes and their association with atopic dermatitis at 2 years of age. (PubMed)

Prenatal perfluorooctanoic acid exposure and glutathione s-transferase T1/M1 genotypes and their association with atopic dermatitis at 2 years of age. Perfluoroalkyl substance (PFAS) exposure was found associated with atopic diseases. Atopic dermatitis (AD) is a childhood skin disorder. However, the effect of interaction between PFASs and glutathione S-transferase (GST) T1/M1 genotype on AD remains unclear.To investigate the association between gene-environmental interaction and childhood AD

Full Text available with Trip Pro

2019 PLoS ONE

17. Measurement of trihydroxy-linoleic acids in stratum corneum by tape-stripping: Possible biomarker of barrier function in atopic dermatitis. (PubMed)

Measurement of trihydroxy-linoleic acids in stratum corneum by tape-stripping: Possible biomarker of barrier function in atopic dermatitis. Epidermal ceramides are indispensable lipids that maintain the functions of the stratum corneum. Esterified omega-hydroxyacyl-sphingosine (EOS) ceramide with a linoleate moiety is one of the most important ceramide species for forming cornified lipid envelopes. This linoleate moiety is eventually metabolized to trihydroxy-linoleic acid (triol, 9,10,13 (...) -trihydroxy-11E-octadecenoic acid). Thus, we assumed that a decrease of triols might reflect skin barrier dysfunction. Against this background, the purposes of this study were to measure the triols by a simple tape-stripping method and to determine the correlation between the amount of triols and transepidermal water loss (TEWL) as an indicator of barrier dysfunction in atopic dermatitis patients. Twenty Japanese subjects with normal skin and 20 atopic dermatitis patients were enrolled in this study. TEWL

Full Text available with Trip Pro

2019 PLoS ONE

18. [Patient education for adults with atopic dermatitis according to the ARNE concept]. (PubMed)

[Patient education for adults with atopic dermatitis according to the ARNE concept]. Atopic dermatitis (AD) represents a chronic inflammatory skin disease showing a 1-year prevalence of 2-3% during adulthood. In a national randomized, controlled multicenter study initiated by the "Arbeitsgemeinschaft Neurodermitisschulung im Erwachsenenalter" (ARNE, Working Group on Educational Training for Adults with Atopic Dermatitis) a program for structured patient education conducted

2018 Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete

19. Noninvasive monitoring of plant-based formulations on skin barrier properties in infants with dry skin and risk for atopic dermatitis (PubMed)

Noninvasive monitoring of plant-based formulations on skin barrier properties in infants with dry skin and risk for atopic dermatitis Dry skin and the associated impaired epidermal barrier function are postulated to constitute a major element in the development of atopic dermatitis.The aim of this study was to evaluate the effect of two plant-based formulations on the epidermal barrier function in a defined cohort of infants with a predisposition for atopic dermatitis.Over a period of 16 weeks (...) , 25 infants who were ages 3 to 12 months and had an atopic predisposition and dry skin received two emollients that contained pressed juice of the ice plant. The infants received both cream and lotion on the forearm, only cream on the face, and only lotion on the leg. Stratum corneum hydration (SCH), transepidermal water loss (TEWL), skin surface pH, and sebum were assessed on the infants' forehead, leg, and forearm. The Scoring Atopic Dermatitis (SCORAD) index was used for the clinical

Full Text available with Trip Pro

2018 International journal of women's dermatology

20. Dupilumab for treating moderate to severe atopic dermatitis

Dupilumab for treating moderate to severe atopic dermatitis Dupilumab for treating moder Dupilumab for treating moderate to ate to se sev vere atopic dermatitis ere atopic dermatitis T echnology appraisal guidance Published: 1 August 2018 nice.org.uk/guidance/ta534 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent the view of NICE (...) . Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Dupilumab for treating moderate to severe atopic dermatitis (TA534) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 21Contents Contents 1 Recommendations 4 2 Information about dupilumab 6 3

2018 National Institute for Health and Clinical Excellence - Technology Appraisals

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>